Navigation Links
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
Date:5/20/2009

NANTONG CITY, China, May 20 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to provide an update on the Company's progress to date this year and guidance on its projected financial performance for the balance of 2009.

Financial Highlights:

  • In Q1 2009, the Company's total revenue increased to RMB 4.60 million (US $0.68 million), representing a 127 percent increase year-over-year from the same period in 2008, when total sales were RMB 2.0 million (US $.29 million).
  • Also in Q1, the Company signed sales contracts for a total 1.5 millions units for Cisatracurium Besylate, Sinobiopharma's flagship drug, with business agents who distribute the Company's products in 30 provinces and key major cities throughout China. Total turnover is projected to be more than RMB 105 million (US $15.3 million), of which 70 percent will be Sinobiopharma profit.

Sales, Production and Marketing Highlights:

  • Sales of Cisatracurium Besylate increased by more than 200 percent from 2007 to 2008. Sales of 1.5 million units are projected in 2009. Sinobiopharma's patented formulation of Cisatracurium Besylate is now China's top-selling pre-surgical skeletal muscle relaxant.
  • Sales of Clindamycin, an antibiotic, increased by 150 percent from 2007 to 2008. Sales of 1 million units are projected in 2009.
  • The Company is currently in the process of launching in the domestic Chinese market. Sinobiopharma's formulation of this antihypertensive is the world's first in capsule form, making it easier to swallow. Sales of more than 500,000 capsules are projected in 2009. As the first Chinese maker of the latest generation of this drug, the Company's has multiple competitive advantages, including lower cost of active pharmaceutical ingredients (API), the ca
    '/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. SemBioSys updates Apo AI development program
9. Strategic Diagnostics Updates Roth Conference Presentation Time
10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
11. SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 BioStructures, LLC, a privately ... a milestone of 4,000 implantations of Signafuse® Bioactive ... in early 2014 as a bone void filler ... procedures.  This is a distinguished status among recently ... of new synthetic products have received clearance with ...
(Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
(Date:7/27/2015)... - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the ... the treatment of cancer, today provides the following financial ... a $1,000,000 unit offering private placement.  This financing is ... Company at a price of $0.06 per unit.  Each ... common share purchase warrant.  Each whole warrant is exercisable ...
(Date:7/27/2015)... 27, 2015   Inocucor Technologies Inc ., ... accelerators for farmers, has received a notice of ... for its patent application to protect Inocucor consortia ... and enhance yields on farms and in greenhouses. ... live IN-M1 microbial consortium and its fermentation byproducts, ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... BioBehavioral Diagnostics Company announced today that its poster was ... via a rigorous peer-review process and included as a ... the American Academy of Child and Adolescent Psychiatry (AACAP) ... Sumner, M.D., the company,s Chief Medical Officer and Senior ...
... ... biotech corn product for food, feed, import and processing jointly developed by DuPont business ... Company. Corn products containing the Herculex® RW protection trait stacked with Roundup Ready® ... Union (EU). , ...
... 2 Laureate Pharma, Inc., a full-service biopharmaceutical ... development and manufacture of monoclonal antibody products, fusion ... the addition of three new members to its ... three new team members with such extensive experience ...
Cached Biology Technology:Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 2Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 3Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD Drug Trials 4European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing 2European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing 3Laureate Pharma Welcomes Three New Members to Business Development Team 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... Institute near Cambridge, supported by the Alzheimer,s Research ... Council (BBSRC), have discovered that the brain,s circuitry ... ageing such as Alzheimer,s disease. The findings were ... Alzheimer,s disease causes nerve cells in the ...
... The Stowers Institute,s Linheng Li Lab has identified the precise ... were published today in the Advance Online Publication of ... of the Institute,s support facilities to develop a new technology ... to monitor the dynamic behavior of stem cells. This technology ...
... NY, December 4, 2008Researchers are taking a closer look ... to demonstrate that inhibiting this biological route suppresses tumor ... ( GEN ). The pathway is involved in angiogenesis, ... part of the PI3/AKT/mTOR pathway, which plays a key ...
Cached Biology News:Maintaining the brain's wiring in aging and disease 2Stowers Institute's Linheng Li Lab expands understanding of bone marrow stem cell niche 2
Recombinant Feline IL-12/IL-23 p40...
Request Info...
Recombinant Equine IL-6...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Biology Products: